国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01099 国药控股

国庆日休市 09-30 16:08:27

14.860

+0.120

+0.81%

最高14.920	最低14.640	成交量614.68万
今开14.750	昨收14.740	日振幅1.90%
总市值463.78亿	流通市值199.39亿	总股本31.21亿
成交额9,119万	换手率0.46%	流通股本13.42亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01099","market":"HK","secType":"STK","nameCN":"国药控股","latestPrice":14.86,"timestamp":1790755707002,"preClose":14.74,"halted":0,"volume":6146766,"delay":0,"changeRate":0.008141112618724506,"floatShares":1341810740,"shares":3121000000,"eps":2.29,"marketStatus":"国庆日休市","change":0.12,"latestTime":"09-30 16:08:27","open":14.75,"high":14.92,"low":14.64,"amount":91185565,"amplitude":0.018996,"askPrice":14.89,"askSize":625200,"bidPrice":14.86,"bidSize":202000,"shortable":3,"etf":0,"ttmEps":2.620836,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790904600000},"marketStatusCode":7,"adr":0,"listingDate":1253635200000,"exchange":"SEHK","adjPreClose":14.74,"dividendRate":0.053156,"openAndCloseTimeList":[[1790731800000,1790740800000],[1790744400000,1790755200000]],"volumeRatio":1.715378536861389,"lotSize":400,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SNP.HK","impliedVol":0.2454,"impliedVolPercentile":0.2735},"requestUrl":"/m/hq/s/01099","defaultTab":"news","newsList":[{"id":"1165151734","title":"国药控股：FMR LLC减持，好仓比例降至3.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165151734","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165151734?lang=zh_cn&edition=full","pubTime":"2026-09-29 17:23","pubTimestamp":1790673821,"startTime":"0","endTime":"0","summary":"FMR LLC于2026年9月24日以每股均价14.6610港元场外卖出国药控股股份2402.12万股，涉资约3.52亿港元。该笔为场外交易（代价性质：现金），未经联交所公开市场撮合，不属二级市场直接买卖。FMR LLC此次减持前持有国药控股好仓7762.30万股，占比5.78%；减持后持股量为5360.18万股，好仓比例降至3.99%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670405870","title":"FMR LLC减持国药控股(01099)73.24万股 每股作价约15.01港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670405870","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670405870?lang=zh_cn&edition=full","pubTime":"2026-09-27 18:50","pubTimestamp":1790506221,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月21日，FMR LLC减持国药控股(01099)73.24万股，每股作价15.0147港元，总金额约为1099.68万港元。减持后最新持股数目约为8041.37万股，最新持股比例为5.99%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1197","BK1500","LU0640798160.USD","EWH","LU1115378108.SGD","BK1515","01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670405877","title":"Lazard Asset Management LLC减持国药控股(01099)73.88万股 每股作价约15.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670405877","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670405877?lang=zh_cn&edition=full","pubTime":"2026-09-27 18:44","pubTimestamp":1790505855,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月21日，Lazard Asset Management LLC减持国药控股(01099)73.88万股，每股作价15.1035港元，总金额约为1115.85万港元。减持后最新持股数目约为1.88亿股，最新持股比例为13.99%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1500","01099","BK1197","BK1515","LU0640798160.USD","LU1115378108.SGD","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127783209","title":"国药控股：Lazard Asset Management LLC减持，好仓比例降至13.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127783209","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127783209?lang=zh_cn&edition=full","pubTime":"2026-09-25 17:42","pubTimestamp":1790329332,"startTime":"0","endTime":"0","summary":"Lazard Asset Management LLC于2026年9月21日在联交所场内以每股均价15.1035港元卖出国药控股（01099）73.88万股，涉资约1115.85万港元，属场内主动交易，即在二级市场直接买卖股份。Lazard Asset Management LLC此次减持前持有国药控股好仓1.88亿股，占比14.04%；减持后持股量为1.88亿股，好仓比例降至13.99%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132051614","title":"国药控股：FMR LLC减持，好仓比例降至5.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=1132051614","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132051614?lang=zh_cn&edition=full","pubTime":"2026-09-25 17:25","pubTimestamp":1790328312,"startTime":"0","endTime":"0","summary":"FMR LLC于2026年9月21日在联交所场内以每股均价15.0147港元卖出国药控股（01099）股份73.24万股，涉资约1099.68万港元，属场内主动交易，即在二级市场直接买卖股份。FMR LLC此次减持前持有国药控股好仓8114.61万股，占比6.05%；减持后持股量为8041.37万股，好仓比例降至5.99%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161744276","title":"国药控股2026年中期营收2,828.00亿元，经调整净利润51.80亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1161744276","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161744276?lang=zh_cn&edition=full","pubTime":"2026-09-23 06:22","pubTimestamp":1790115736,"startTime":"0","endTime":"0","summary":"本期，国药控股实现营收2,828.00亿元，同比下降1.13%；经调整净利润51.80亿元，同比下降2.95%。毛利率为6.74%，较上年同期下降0.37个百分点；经营利润率2.53%，较上年同期下降0.07个百分点。同期经营活动现金流净流出237.63亿元，去年同期净流出341.11亿元，流动性状况总体稳健。报告期内，销售费用率2.59%、管理费用率1.23%、财务费用率0.29%，整体费用率4.11%，同比下降0.27个百分点。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国药控股2026年中期营收2,828.00亿元，经调整净利润51.80亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181970146","title":"国药控股（01099）特别股东大会通过15项董事重选议案并选举新一届董事会职务","url":"https://stock-news.laohu8.com/highlight/detail?id=1181970146","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181970146?lang=zh_cn&edition=full","pubTime":"2026-09-15 18:13","pubTimestamp":1789467205,"startTime":"0","endTime":"0","summary":"国药控股股份有限公司（01099）9月16日公告称，公司于2026年9月15日在上海召开股东特别大会，15项有关第七届董事会成员重选及薪酬授权的普通决议案全部获股东以过半数票赞成通过。会议现场及受委托出席的股东合计持有2,547,078,853股股份，占已发行股份总数的81.62%。截至会议召开日，公司已发行股份总数为3,120,656,191股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667617050","title":"前任合作匆匆落幕后，弥可保推广权易手国药控股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667617050","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667617050?lang=zh_cn&edition=full","pubTime":"2026-09-15 16:06","pubTimestamp":1789459577,"startTime":"0","endTime":"0","summary":"上任合作刚满一年，弥可保迎来新的推广方。9月14日晚间，卫材中国宣布与国药控股就弥可保针剂签署推广合作协议。值得注意的是，就在两个半月前，卫材中国与誉衡药业子公司天津博达的推广合作才刚刚终止。此前，卫材中国将该产品大陆地区独家推广权授予天津博达，合作仅维持一年多便匆匆宣告终止。彼时，誉衡药业曾在公告中透露，该合作产品对公司的收入贡献占整体收入的比例较低。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609153874698249.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609153874698249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01099","LU1115378108.SGD","BK1197","LU0640798160.USD","BK1500","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666931415","title":"Lazard Asset Management LLC增持国药控股(01099)95.96万股 每股作价约15.68港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666931415","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666931415?lang=zh_cn&edition=full","pubTime":"2026-09-10 19:55","pubTimestamp":1789041340,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月4日，Lazard Asset Management LLC增持国药控股(01099)95.96万股，每股作价15.6782港元，总金额约为1504.48万港元。增持后最新持股数目约为1.88亿股，最新持股比例为14%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494614.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1500","01099","LU1115378108.SGD","BK1515","BK1197","EWH","LU0640798160.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665334495","title":"国药控股（01099）宣布与翰森制药（03692）开启全周期战略协同合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2665334495","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665334495?lang=zh_cn&edition=full","pubTime":"2026-09-08 12:34","pubTimestamp":1788842076,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国药控股（01099）9月8日宣布，近日，公司已与翰森制药（03692）达成战略合作。基于双方多年深度合作积淀，围绕深化工商协同、赋能产业高质量发展目标，双方签署战略合作协议，同步落地广阔市场、医疗准入、零售、DTP专项合作协议，推动工商合作由传统业务对接，全面升级为全链条、全周期战略协同。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/MGM1MTEwODE5MDc1ODM4MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MGM1MTEwODE5MDc1ODM4MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991005","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1500","01099","BK1197","BK1515","BK1589","LU0640798160.USD","BK1191","LU1115378108.SGD","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665313965","title":"贝莱德在国药控股的H股好仓比例下降0.15%至8.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665313965","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665313965?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:20","pubTimestamp":1788772800,"startTime":"0","endTime":"0","summary":"南财智讯9月7日电，香港交易所披露信息显示，BlackRock,Inc.（贝莱德）在国药控股的H股好仓（L）比例于9月2日从9.07%下降至8.92%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866754446.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866754446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0640798160.USD","BK1515","BK1197","LU1115378108.SGD","01099","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665398249","title":"【券商聚焦】中信建投：上半年收入与利润双增，医药行业步入新发展周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2665398249","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665398249?lang=zh_cn&edition=full","pubTime":"2026-09-07 09:04","pubTimestamp":1788743053,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业整体收入与扣非净利润实现双增长，创新药、CXO、制药装备及科学试剂等板块积极复苏，行业步入新发展周期。创新药收入+58.68%，扭亏为盈，出海总金额超900亿美元，全年有望超越2025年水平，国际化持续兑现；CXO收入+25.2%，扣非净利润+66.5%，订单旺盛，上行周期确立。随着集采出清、创新放量、出海落地及上游国产化提升，行业有望开启高质量发展周期，龙头将持续受益。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990791","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2778985437.USD","LU0828237510.HKD","LU0417516902.SGD","LU0348825331.USD","LU2476274308.USD","LU1720050803.USD","01789","BK1100","601066","HK0000165453.HKD","KCE","BK1141","IE00B5MMRT66.SGD","01530","09926","BK1585","LU1115378108.SGD","LU0228659784.USD","BK1207","02268","09688","KURE","LU2328871848.SGD","BK1191","LU2476274720.SGD","LU0348827113.USD","02367","06821","03933","LU2399975544.HKD","BK1161","LU0588546209.SGD","BK1588","LU0640798160.USD","SG9999004311.SGD","LU1969619763.USD","BK1574","02228","LU2488822045.USD","BK1515","LU1770034418.SGD","06160","01099","02196","BK1583","BK1197","BK1500","IE00B3M56506.USD","BK1593","IE00BPRC5H50.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131274850","title":"国药控股8月股份变动月报显示股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1131274850","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131274850?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:53","pubTimestamp":1788512032,"startTime":"0","endTime":"0","summary":"国药控股股份有限公司于2026年9月4日公布截至2026年8月31日的股份变动月报。报告期内，各类已发行股份及注册股本均未发生增减变动。报告期内，未出现新增发行、股份购回、注销及库藏股变化，股权激励及期权事项亦无变动。公司表示，截至本月末，其H股维持充足的公眾持股比例，符合香港联合交易所有限公司《上市规则》等法律法规要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664878268","title":"贝莱德在国药控股的H股好仓比例下降0.18%至8.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664878268","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664878268?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:24","pubTimestamp":1788427440,"startTime":"0","endTime":"0","summary":"南财智讯9月3日电，香港交易所披露信息显示，BlackRock,Inc.（贝莱德）在国药控股的H股好仓（L）比例于8月31日从9.11%下降至8.93%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609033864136039.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609033864136039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01099","BK1500","BK1515","LU0640798160.USD","BK1197","LU1115378108.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119060311","title":"国药控股（01099）将于9月15日召开股东特别大会，审议15名董事连任","url":"https://stock-news.laohu8.com/highlight/detail?id=1119060311","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119060311?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:22","pubTimestamp":1788168152,"startTime":"0","endTime":"0","summary":"国药控股8月31日发布通告，宣布公司将于2026年9月15日（星期二）上午9时在上海市黄浦区龙华东路385号国药控股大厦1401会议室召开股东特别大会。会议拟审议以下普通决议案：。公司H股股东名册将于9月10日至9月15日暂停过户。欲在大会上行使表决权的H股股东，须于9月9日16:30前将过户文件递交至香港中央证券登记有限公司。股东可委任代理人出席并投票，会议预计不超过半天，相关交通及住宿费用由股东自理。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180532970","title":"国药控股（01099）拟重选全部董事并于9月15日召开股东特别大会","url":"https://stock-news.laohu8.com/highlight/detail?id=1180532970","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180532970?lang=zh_cn&edition=full","pubTime":"2026-08-31 16:41","pubTimestamp":1788165663,"startTime":"0","endTime":"0","summary":"2026年8月31日，国药控股股份有限公司发布通函，披露第七届董事会成员重选安排，并宣布将于2026年9月15日（星期二）上午9时正在中国上海市黄浦区龙华东路385号国药控股大厦1401会议室召开股东特别大会。通函显示，公司第六届董事会任期将于2026年9月14日届满，董事会已于2026年8月21日通过决议，提请股东大会审议全部董事的重选事项。根据公司章程，上述候选人须经股东特别大会批准后方可就任。公司表示，将与获选董事分别签署服务合约。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662066765","title":"国药控股(01099)：国药一致中期归母净利润6.06亿元 同比减少8.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662066765","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662066765?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:56","pubTimestamp":1787911018,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药控股(01099)发布国药一致截至2026年6月30日止六个月业绩，营业总收入362.66亿元人民币，同比减少1.44%;归属于上市公司股东的净利润6.06亿元，同比减少8.97%;基本每股收益0.99元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488058.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01099","000028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150689680","title":"国药控股（01099）披露子公司一致药业2026年中期报告：营收362.66亿元，同比降1.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1150689680","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150689680?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:53","pubTimestamp":1787910812,"startTime":"0","endTime":"0","summary":"2026年8月28日，国药控股发布海外监管公告，披露其A、B股子公司——国药集团一致药业股份有限公司2026年半年度业绩。报告期内，公司主要财务数据如下：。报告期内研发费用投入3482.13万元，同比减少70.06%。截至报告期末，公司继续强化分销与零售双轮驱动，保持市场份额的同时，面对行业价格压力与政策变动，采取精益管理与结构调整措施。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162658735","title":"国药控股 (01099.HK)：子公司国药一致 2026 年上半年营收 362.66 亿元，同比微降 1.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162658735","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162658735?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:46","pubTimestamp":1787910393,"startTime":"0","endTime":"0","summary":"国药控股股份有限公司8 月 28 日公告披露，其附属公司国药集团一致药业股份有限公司截至 2026 年 6 月 30 日止六个月的主要未经审计财务数据。报告期内，国药一致实现营业总收入 362.66 亿元，较上年同期的 367.97 亿元下降 1.44%。资产规模方面，截至 2026 年 6 月 30 日，国药一致总资产为 481.71 亿元，较期初的 490.96 亿元减少 1.89%；归属于上市公司股东的净资产为 188.73 亿元，较期初的 186.10 亿元增长 1.42%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662795539","title":"高盛：降国药控股(01099.HK)目标价至18.46港元 第二季业绩符预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2662795539","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662795539?lang=zh_cn&edition=full","pubTime":"2026-08-26 15:44","pubTimestamp":1787730269,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1500","01099","BK1515","LU0640798160.USD","LU1115378108.SGD","BK1197"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinopharmgroup.com.cn","stockEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0413},{"period":"3month","weight":-0.0956},{"period":"6month","weight":-0.2535},{"period":"1year","weight":-0.1485},{"period":"ytd","weight":-0.1967}],"compareEarnings":[{"period":"1week","weight":-0.0089},{"period":"1month","weight":-0.0373},{"period":"3month","weight":0.0676},{"period":"6month","weight":-0.02},{"period":"1year","weight":-0.0835},{"period":"ytd","weight":-0.0397}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"国药控股股份有限公司是一家主要从事药品、医疗保健产品及医疗器械批发和零售业务的中国公司。该公司通过四个部门运营业务。医药分销部门为国内外药品及保健品制造商及其他供货商提供分销、物流及其他加值服务。器械分销部门向客户分销医疗器材。医药零售业务部门拥有直接经营或特许经营的零售药局网路。其他业务部门从事药品、化学试剂及实验室用品的制造与销售。","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.004652},{"month":2,"riseRate":0.588235,"avgChangeRate":0.029404},{"month":3,"riseRate":0.470588,"avgChangeRate":0.00701},{"month":4,"riseRate":0.411765,"avgChangeRate":0.016475},{"month":5,"riseRate":0.588235,"avgChangeRate":-0.009205},{"month":6,"riseRate":0.411765,"avgChangeRate":-0.006214},{"month":7,"riseRate":0.529412,"avgChangeRate":-0.008781},{"month":8,"riseRate":0.411765,"avgChangeRate":0.005041},{"month":9,"riseRate":0.411765,"avgChangeRate":-0.012951},{"month":10,"riseRate":0.647059,"avgChangeRate":0.042281},{"month":11,"riseRate":0.470588,"avgChangeRate":-0.00729},{"month":12,"riseRate":0.529412,"avgChangeRate":-0.004119}],"exchange":"SEHK","name":"国药控股","nameEN":"SINOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供国药控股(01099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"国药控股,01099,国药控股股票,国药控股股票老虎,国药控股股票老虎国际,国药控股行情,国药控股股票行情,国药控股股价,国药控股股市,国药控股股票价格,国药控股股票交易,国药控股股票购买,国药控股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供国药控股(01099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}